Bharat Biotech, Sydney ID MoU to transform vaccine research

Bharat Biotech International Limited, a world leading vaccines & bio-therapeutics manufacturer and the University of Sydney Infectious Diseases Institute (Sydney ID) today announced a Memorandum of Understanding (MoU) to advance vaccine research initiatives, strengthen academic-industry partnerships and augment global efforts to combat infectious diseases.

The international agreement aims to build strong sectoral and cross-organisational collaborations to design novel methodologies to tackle future epidemics and infectious diseases. Furthermore, leverage academia-industry strengths for advancing the science of vaccines and biotherapeutics.

Dr. Krishna Ella, Executive Chairman at Bharat Biotech said, “This agreement reflects our ethos to facilitate collaborative research, foster innovation, and further advance the science of vaccine technology. Mutually, we are excited about the new opportunities to strengthen our shared vision, leverage the prowess of education, research capabilities to help build a healthier universe and improve people’s lives by developing safer vaccine platforms. Most importantly, build the talent of young scientists with a passion to innovate.”

Bharat Biotech , Sydney ID to make lasting impact on preventive healthcare research

Professor Jamie Triccas, Deputy Director at Sydney ID, emphasised the significance of this collaboration, saying, “Positioning Sydney ID on a global scale to drive innovation and highlight our expertise in the development of new vaccines and biotherapeutics is paramount. The reputational and societal impacts of developing novel vaccines to eradicate human and animal diseases that are safe, affordable, and effective cannot be overstated. Together with Bharat Biotech International Limited, we aim to make a lasting impact on global health.”

Vaccines are the most effective and cost-effective way to protect billions of people worldwide, with vaccine development potentially transforming health by removing the burden of life-threatening infectious diseases from the population. India’s capabilities in the manufacturing of vaccines came to the fore during the COVID-19 pandemic, where companies such as Bharat Biotech, were able to provide vaccines that met over 60% of the world’s demand and supplied over 2.4 billion doses of COVID-19 vaccines. India continues to make significant R&D investments to develop a roadmap for the design and delivery of vaccine development for a future pandemic.